Shih-Fong Chen

Title: The Innovative Contributions of Shih-Fong Chen

Introduction

Shih-Fong Chen is a notable inventor based in Apex, NC (US). He has made significant contributions to the field of oncology through his innovative research and patent work. His expertise lies in the development of therapeutic agents aimed at inhibiting tumor growth.

Latest Patents

Shih-Fong Chen holds a patent titled "Use of adenosine A3 receptor antagonists to inhibit tumor growth." This patent describes a method for inhibiting tumor growth and metastasis through the administration of adenosine A3 receptor antagonists. The antagonists can be administered in combination with other anti-tumor agents, such as anti-angiogenic agents and cytotoxic agents. This innovative approach targets both the tumor cells and the vasculature that supports their growth.

Career Highlights

Shih-Fong Chen is associated with King Pharmaceuticals Research and Development, Inc., where he has been instrumental in advancing cancer treatment methodologies. His work has contributed to the understanding of how adenosine A3 receptor antagonists can be effectively utilized in clinical settings.

Collaborations

Throughout his career, Shih-Fong Chen has collaborated with esteemed colleagues, including Edward Leung and Pier Giovanni Baraldi. These collaborations have fostered a productive research environment, leading to advancements in cancer therapeutics.

Conclusion

Shih-Fong Chen's innovative work in the field of oncology, particularly through his patent on adenosine A3 receptor antagonists, showcases his commitment to improving cancer treatment. His contributions continue to influence the development of effective therapeutic strategies against tumor growth.